Rheumatoid and Spondyloarthritis Treatment Trial
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial is for people with rheumatoid arthritis or spondyloarthritis who haven't responded well to standard treatments. It aims to study and improve care for those needing advanced biologic or synthetic therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have rheumatoid arthritis (meeting ACR/EULAR guidelines) or spondyloarthritis (meeting ASAS criteria) in the spine and/or joints.
- For rheumatoid arthritis: You have tried and failed, or cannot take, methotrexate or Arava (leflunomide).
- For spondyloarthritis: You have tried and failed at least two different NSAIDs (like ibuprofen or naproxen).
- You are about to start, or are already on, biologic or advanced synthetic medication for your condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry is collecting information about people with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis who are starting or needing biologic or targeted medicines. It may help researchers better understand how these treatments work in real life.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.